Navigation Links
Strides Made in Lung Cancer Treatment
Date:1/13/2010

Genetic testing, biomarkers finally giving clues to elusive disease, experts report

WEDNESDAY, Jan. 13 (HealthDay News) -- Advances in genetics and biomarker identification and testing are finally bearing fruit in the battle against lung cancer, a new set of studies suggests.

Until now, lung cancer has lagged behind other malignancies when it comes to identifying molecular features of the disease and developing specific drugs to target those features.

"Lung cancer is a very vexing problem. In the U.S., approximately 200,000 people will be diagnosed this year and the sad part of it is almost as many will die," said Dr. Roy Herbst, chief of thoracic medical oncology at the University of Texas M. D. Anderson Cancer Center in Houston. "This disease tends to present having already spread, and it's very heterogenous. If we're going to make the next hurdle of personalized care, we need to better understand the tumor and use that knowledge to treat patients in more specific, effective and less toxic ways."

Herbst spoke at a Tuesday news conference that highlighted research being presented this week at a lung cancer conference in Coronado, Calif., being sponsored by the American Association for Cancer Research (AACR) and the International Association for the Study of Lung Cancer (IASLC).

"As we begin to understand the molecular basis for cancer, we're able to better characterize patients and better able to predict which drugs will or will not work," added Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge, La.

Breakthroughs in targeted lung cancer medicine have come only recently, namely with the drugs gefitinib (Iressa) and erlotinib (Tarceva), which aim for the epidermal growth factor receptor (EGFR) gene.

Now, lung cancer scientists are opening the envelope of molecular-based medicine even further.

Here are summaries of five papers being featured at the conference.

  • UCLA researchers report that a set of 40 biomarkers in the blood correctly identified patients with lung cancer and patients without lung cancer the vast majority of the time (88 percent and 79 percent, respectively). "Most of the biomarkers had to do with inflammation and other kinds of immunomodulatory approaches," explained Dr. Matthew Meyerson, a professor of pathology at Harvard Medical School. "This is not intended yet for clinical testing but it shows the potential power of serum-based profiling for early detection of lung cancer." Early detection, of course, is the key to recovery.
  • A panel of 93 genes indicating the presence of EGFR mutations in non-small cell lung cancer (the most common type of lung cancer) predicted which patients have a better prognosis and could benefit from drugs targeting this pathway, scientists from M.D. Anderson Cancer Center at the University of Texas found. "This set of gene expression changes can be useful in determining which patients harbor such mutations which might be sensitive to targeted therapies directed at that particular mutation," said Tyler Jacks, AACR president and director of the David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology in Boston.
  • University of Colorado investigators found that patients with non-small cell lung cancer who also had certain configurations of the anaplastic lymphoma kinase (ALK) gene responded better to a new drug which inhibits activity of this gene. About a quarter of patients who took the drug saw their tumors shrink by 20 percent or more, said Dr. Paul A. Bunn Jr., IASLC executive director and the James Dudley chair in cancer research at the University of Colorado. "Some had complete dissolution of the tumor so it couldn't be seen any more. That almost never happens with chemo," he noted. Participants had received multiple other treatments before enrolling in the trial.
  • Belgian scientists identified three groups of lung tumors based on how they grow and destroy other tissue. Each separate type of behavior correlated with a different prognosis. The researchers are still searching for underlying molecular features that explain the behavior differences, said Dr. David Carbone, the Harold L. Moses chair in cancer research and director of the Specialized Program of Research Excellence in Lung Cancer at Vanderbilt-Ingram Cancer Center.
  • Finally, a set of changes in microRNA expression could help determine which patients should be funneled towards conventional chemotherapy and which should receive other types of treatment, researchers from Arizona report. "MicroRNAs are small RNAS that control the expression of many genes," explained Jacks. "This set of three microRNAs correlated with resistance to therapy. This needs to be validated, but could be useful in diagnosing patients and applying relevant therapies."

More information

The U.S. National Cancer Institute has more on lung cancer.



SOURCES: Jay Brooks, chairman, hematology/oncology, Ochsner Health System, Baton Rouge, La.; Jan. 12, 2010, teleconference with Roy Herbst, M.D., Ph.D., chief, thoracic medical oncology, University of Texas M. D. Anderson Cancer Center; Tyler Jacks, Ph.D., AACR president and director, David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology; Paul A. Bunn Jr., M.D., IASLC executive director and professor of medicine and James Dudley chair in cancer research, University of Colorado, Denver; David Carbone, M.D., Ph.D., Harold L. Moses chair in cancer research and director, Specialized Program of Research Excellence in Lung Cancer, Vanderbilt-Ingram Cancer Center; and Matthew Meyerson, M.D., Ph.D., professor of pathology, Harvard Medical School; study abstracts


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Twenty-Five Individuals Honored by Yoplait(R) for Making Extraordinary Strides in the Fight Against Breast Cancer
2. GREAT STRIDES Walks for Cystic Fibrosis Slated for 47 States This Weekend
3. Gentiva Safe Strides(R) Home Balance Therapy Program is Reducing Risk of Dangerous Falls and Relieving Pain for Thousands of Older Americans
4. Stroller Strides(R) Franchises Succeed Despite Economic Climate
5. Stroller Strides(R) Signs Pampers(R) as Premier Sponsor for 2009
6. Womans Day Presents the Sixth Annual Red Dress Awards Honoring Women Making Strides in the Fight Against Heart Disease
7. Cystic Fibrosis Foundation Launches GREAT STRIDES Walks Nationwide at 600 Locations
8. Strides Made in Hemophilia Research
9. KePRO Employees Make "Great Strides" Towards Cure for Cystic Fibrosis
10. Lab Study Makes Strides in Mending Hearts
11. Strides Made in Tonsil Cancer Repair
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... June 27, 2017 , ... ... Scholarship Foundation Fundraiser hygiene symposium in Mystic, CT. Covering the process and maintenance ... their experience in these popular periodontal procedures. Drs. Toback and Urbanski practice as ...
(Date:6/27/2017)... ... June 27, 2017 , ... A+ Orthodontics ... dental specialty that focuses on treating alignment and occlusion irregularities. Treatment often includes ... , North Hollywood dentist , Dr. Garemani, along with Dr. Reza ...
(Date:6/26/2017)... ... 26, 2017 , ... Antoine Dental Center is now offering various types of dental ... act as a support for prosthetic teeth, such as crowns, bridges, or dentures. An implant ... a sturdy, lasting new root for the tooth. , Several types of dental implants ...
(Date:6/26/2017)... ... June 26, 2017 , ... A ... revolutionizing the way women look and feel about themselves and their sexual encounters. ... sexual dysfunction and urinary leakage head on with a ground breaking medical technique ...
(Date:6/26/2017)... ... June 26, 2017 , ... New patients with missing teeth ... or without a referral. Dr. Cotey is a trusted dentist who has placed many ... option. , Patients with missing teeth in Fitchburg, WI, are encouraged to find out ...
Breaking Medicine News(10 mins):
(Date:6/5/2017)... OMAHA, Neb. , June 5, 2017 /PRNewswire/ ... chair in the United States ... chair that helps a fallen person up to an ... is easily assembled and operated by one assistant and ... hand. It is simple enough that a child can ...
(Date:5/30/2017)... , May 30, 2017 DarioHealth Corp. (NASDAQ: DRIO), ... data solutions, today announced that it will be presenting at the ... 8:00 AM PT. Erez Raphael , CEO, of DarioHealth will ... conference will be held on June 6th & 7th, 2017 at ... in the small / micro-cap space. ...
(Date:5/26/2017)... , May 26, 2017  Endo International plc (NASDAQ: ... , President and CEO, will represent the Company in a ... Healthcare Conference on Tuesday, June 13, 2017 at 10:40 a.m. ... at Terranea Resort in Rancho Palos Verdes, CA. ... for the event will be available on the Company,s website ...
Breaking Medicine Technology: